Research ArticleBrief Communication
Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CT
Josef J. Fox, Estelle Autran-Blanc, Michael J. Morris, Somali Gavane, Sadek Nehmeh, André Van Nuffel, Mithat Gönen, Heiko Schöder, John L. Humm, Howard I. Scher and Steven M. Larson
Journal of Nuclear Medicine November 2011, 52 (11) 1727-1732; DOI: https://doi.org/10.2967/jnumed.111.089326
Josef J. Fox
Estelle Autran-Blanc
Michael J. Morris
Somali Gavane
Sadek Nehmeh
André Van Nuffel
Mithat Gönen
Heiko Schöder
John L. Humm
Howard I. Scher
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 52, Issue 11
November 1, 2011
Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CT
Josef J. Fox, Estelle Autran-Blanc, Michael J. Morris, Somali Gavane, Sadek Nehmeh, André Van Nuffel, Mithat Gönen, Heiko Schöder, John L. Humm, Howard I. Scher, Steven M. Larson
Journal of Nuclear Medicine Nov 2011, 52 (11) 1727-1732; DOI: 10.2967/jnumed.111.089326
Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CT
Josef J. Fox, Estelle Autran-Blanc, Michael J. Morris, Somali Gavane, Sadek Nehmeh, André Van Nuffel, Mithat Gönen, Heiko Schöder, John L. Humm, Howard I. Scher, Steven M. Larson
Journal of Nuclear Medicine Nov 2011, 52 (11) 1727-1732; DOI: 10.2967/jnumed.111.089326
Jump to section
Related Articles
Cited By...
- 18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients
- Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging
- Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma
- Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer
- 18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO
- Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
- Measuring Oncogenic Signaling Pathways in Cancer with PET: An Emerging Paradigm from Studies in Castration-Resistant Prostate Cancer